MediWound Ltd. develops and commercializes enzymatic, non-surgical therapies for tissue repair as a global biotechnology company. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets.
News about MDWD commonly covers financial results, corporate updates, NexoBrid commercialization and distribution, BARDA-supported burn-care activity, and the development of EscharEx, an investigational bromelain-based therapy for debridement of chronic and hard-to-heal wounds. Company updates also include clinical data presentations, wound-care conference activity, regulatory filings, and shareholder communications.
MediWound (MDWD) will host a virtual expert event on December 2, 2026, covering EscharEx clinical development and its commercial opportunity. The event begins at 11:00 a.m. Eastern Time. Speakers will discuss Phase II evidence, the ongoing Phase III VALUE study in venous leg ulcers, and assumptions behind Alira Health’s estimated $1.05 billion U.S. annual peak sales potential. A live question-and-answer session will follow, with a replay available on MediWound’s investor website.
MediWound (MDWD) reported third-quarter 2026 revenue of $3.6 million, down from the prior-year quarter as government-related development services revenue declined. Net loss widened to $6.0 million, or $0.46 per basic share, from $2.7 million, or $0.24 per basic share. Gross margin rose to 28.5% from 16.5%.
The company expects the EscharEx Phase III VALUE trial’s interim sample size reassessment and enrollment completion by the end of the first quarter of 2027. A substantial portion of anticipated 2026 revenue depends on uncertain U.S. government funding discussions and subsequent development work. Expanded NexoBrid manufacturing supply is expected in the second half of 2027, subject to regulatory approval.
Cash, cash equivalents and deposits totaled $28.4 million at September 30, versus $53.6 million at year-end 2025. A November public offering raised $17.25 million in gross proceeds.
MediWound (Nasdaq: MDWD) closed its previously announced underwritten public offering, raising gross proceeds of $17.25 million through ordinary share issuance.
The offering comprised 1,380,000 ordinary shares at $12.50 each, including 180,000 shares issued through the full exercise of the underwriter’s option. Gross proceeds are before underwriting discounts, commissions and offering expenses. MediWound intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. acted as sole book-running manager.
MediWound (Nasdaq: MDWD) entered into a firm-commitment underwriting agreement with H.C. Wainwright for an offering expected to raise approximately $15 million. The underwriter agreed to purchase 1,200,000 ordinary shares at a public offering price of $12.50 per share, less underwriting discounts and commissions. Expected gross proceeds exclude those deductions and offering expenses and assume no exercise of the additional-share option.
The underwriter received a 30-day option to purchase up to 180,000 additional ordinary shares at the same public price, less underwriting discounts and commissions. Closing is expected on or about November 5, 2026, subject to customary closing conditions. MediWound intends to use net proceeds for working capital and general corporate purposes.
MediWound (Nasdaq: MDWD) will release its third-quarter 2026 financial results on November 12, 2026, covering the quarter ended September 30. Management will then host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. A webcast replay will be available in the Investors section of the company’s website.
MediWound (MDWD) received an additional $3.3 million in non-dilutive funding from the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid for battlefield burn care.
This award increases the total development program budget to $21.8 million and is intended to support progress through submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. MediWound plans to complete CMC development, establish in-house cGMP manufacturing capabilities, and produce clinical batches for the planned clinical program. The program is within MediWound’s existing North American license agreement with Vericel (VCEL), which holds exclusive commercial and development rights to NexoBrid in North America.
MediWound (MDWD) reported that an independent DSMB recommended its Phase III VALUE study of EscharEx in venous leg ulcers continue without modification.
The DSMB completed a pre-specified periodic safety review of the global, randomized, double-blind, placebo-controlled pivotal trial and did not identify safety concerns. The VALUE study (NCT06568627) is designed to enroll 216 patients across about 40 sites in the U.S., Europe and Israel, randomized 1:1 to EscharEx or placebo. Co-primary endpoints are incidence of complete debridement and facilitation of wound closure over a 12-week wound-management period. A pre-specified interim sample-size reassessment will occur after 65% of patients complete this period, with both the interim reassessment and completion of enrollment expected by the end of the first quarter of 2027.
MediWound (MDWD)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 2:00 p.m. ET.The event will be held at the Lotte New York Palace Hotel in New York City, moderated by Swayampakula Ramakanth of H.C. Wainwright. A live webcast will be accessible on MediWound’s website under Investors > Events & Presentations.
MediWound (Nasdaq: MDWD) reported second quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, with a net loss of $7.4 million ($0.57 per share). First-half 2026 revenue was $4.6 million versus $9.7 million in 2025, and net loss was $10.3 million.
The company reaffirmed 2026 revenue guidance of $24–26 million, supported by BARDA-related programs and a new Master Services Agreement with Vericel under its BARDA contract for NexoBrid, from which revenue is expected in second-half 2026. NexoBrid has been ordered by approximately 80 U.S. burn centers, and Vericel reported its strongest NexoBrid quarter since launch.
Enrollment continues in the global Phase III EscharEx VALUE trial in venous leg ulcers, with interim sample size reassessment and enrollment completion expected by end of first quarter 2027. An independent assessment estimates U.S. peak sales potential for EscharEx at $1.05 billion. Cash, cash equivalents and deposits totaled about $35 million on June 30, 2026, after a first-half cash burn of $20 million.
MediWound (Nasdaq: MDWD) will release its second quarter 2026 financial results for the period ended June 30, 2026 on Thursday, August 13, 2026, followed by a management-hosted conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update.